MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

MDT

95.61

+0.82%↑

VEEV

300.34

+2.34%↑

138.64

-0.03%↓

HQY

89.66

-1.24%↓

PHR.US

22.83

+1.69%↑

Начало・Списък с акции・Altimmune Inc

Altimmune Inc

Затворен

3.92 1.82

Купи Продай

Преглед

Промяна на цената на акция

24 ч

Текуща

Минимум

3.82

Максимум

3.94

Ключови измерители
By Trading Economics
Приходи	-2.6M -22M
Продажби	5K
Марж на печалбата	-442,920
Служители	59
EBITDA	-2.7M -23M

Препоръки
By TipRanks
Препоръки	Купи
12-месечна прогноза	+385.79% upside

Дивиденти
By Dow Jones
Следващи печалби	11.11.2025 г.

Пазарни показатели
By TradingEconomics
Пазарна капитализация	79M 353M
Предишно отваряне	2.1
Предишно затваряне	3.92

Техническа оценка

By Trading Central

Увереност

Bullish Evidence

5.365 / 6.0486 Подкрепа & съпротива

Altimmune Inc Графика

Миналото представяне не гарантира бъдещи резултати.

Свързани новини

2.10.2025 г., 23:30 ч. UTC

Горещи акции

Stocks to Watch: Rumble, Applied Materials, American Outdoor Brands

2.10.2025 г., 21:21 ч. UTC

Печалби

Applied Materials Expects New Export Rule to Hit 2026 Revenue by $600 Million

3.10.2025 г., 00:00 ч. UTC

Придобивния, сливания и поглъщания

Warren Buffett's Berkshire Comes to the Aid of Occidental Petroleum -- Again -- WSJ

2.10.2025 г., 23:40 ч. UTC

Пазарно говорене

Gold Edges Higher, Aided by Risks U.S. Shutdown May Weaken Economy -- Market Talk

2.10.2025 г., 23:39 ч. UTC

Пазарно говорене

Japanese Stocks May Edge Higher, Tracking Wall Street Gains -- Market Talk

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Transaction Remains on Track to Close This Qtr or 1Q 2026 >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Received Regulatory Approval From FERC for Acquisition of Certain Subsidiaries Owning Seven Natural-Gas Generation Facilities From Lotus Infrastructure Partners >VST

2.10.2025 г., 23:29 ч. UTC

Придобивния, сливания и поглъщания

Vistra: Next Step in Acquisition of Gas Generation Fleet With Approval From Federal Energy Regulatory Commission

2.10.2025 г., 23:00 ч. UTC

Пазарно говорене

Warehouse Needs Time to Restore Credibility With Investors -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Scales's JV Buyout Lauded by Bull -- Market Talk

2.10.2025 г., 22:54 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Global Forex and Fixed Income Roundup: Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Synlait Milk Loses Bear Following Sale of North Island Assets -- Market Talk

2.10.2025 г., 22:46 ч. UTC

Пазарно говорене

Global Equities Roundup: Market Talk

2.10.2025 г., 21:17 ч. UTC

Придобивния, сливания и поглъщания

Buffett Scores Win in Berkshire's Deal for Occidental Chemicals Unit -- Barrons.com

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Придобивния, сливания и поглъщания

Energy & Utilities Roundup: Market Talk

2.10.2025 г., 20:50 ч. UTC

Пазарно говорене

Basic Materials Roundup: Market Talk

2.10.2025 г., 20:49 ч. UTC

Придобивния, сливания и поглъщания

OpenAI's Latest Funding Deal Returns Focus to AI Economy, Lifting U.S. Stocks -- WSJ

2.10.2025 г., 20:00 ч. UTC

Придобивния, сливания и поглъщания

Legrand Signs Definitive Agreement To Acquire Avtron Power Solutions, A Global Provider Of Load Banks & Power Quality Solutions >LR.FR

2.10.2025 г., 19:20 ч. UTC

Пазарно говорене

Natural Gas Snaps Winning Streak Despite Small Inventory Rise -- Market Talk

2.10.2025 г., 19:10 ч. UTC

Пазарно говорене

Bank of Canada to Publish Inflation Dashboard in 2026 -- Market Talk

2.10.2025 г., 19:04 ч. UTC

Пазарно говорене

Oil Futures Extend Losses as Markets Brace for Higher Output -- Market Talk

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Expected to Improve Annual Free Cash Flow by More Than $100 M Over Next Several Years and Then Decrease Over Time >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Loss Will Be Excluded From Adjusted EPS >HON

2.10.2025 г., 18:46 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Estimated Impact of Divestiture Will Be One-Time Loss of About $115 M >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Will Have No Further Fincl Exposure to the Transferred Liabilities >HON

2.10.2025 г., 18:45 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Utilized Portion of Cash From Resideo Indemnification and Reimbursement Agreement Termination to Fund Delticus Transaction >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Delticus Assumed Full Responsibility for Administering and Resolving All Current and Future Asbestos-Related Claims >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell and Delticus Contributed About $1.68 B in Cash, as Well as Certain Insurance Assets Related to Legacy Asbestos Liabilities >HON

2.10.2025 г., 18:44 ч. UTC

Придобивния, сливания и поглъщания

Honeywell: Transaction Strengthens Annual Free Cash Flow Generation >HON

2.10.2025 г., 18:43 ч. UTC

Придобивния, сливания и поглъщания

Honeywell Divested All Legacy Bendix Asbestos Liabilities, as Well as Certain Non-Bendix Asbestos Liabilities, to Delticus >HON

Сравнение с други в отрасъла

Ценова промяна

Altimmune Inc Прогноза

Ценова цел

By TipRanks

385.79% нагоре

12-месечна прогноза

Среден 18.8 USD 385.79%

Висок 25 USD

Нисък 12 USD

Според 7 анализатори от Wall Street, предложили 12-месечна ценова цел за Altimmune Inc през последните три месеца.

Консенсусна оценка

By TipRanks

Купи

7 ratings

Купи

Задържане

Продай

Според 7 анализатори, дали борсови рейтинги на Altimmune Inc през последните 3 месеца.

Техническа оценка

By Trading Central

5.365 / 6.0486Подкрепа & съпротива

Recent bullish events outweigh bearish events.

All events are bearish.

Финанси

Продажбени и админисративни разходи

Оперативни разходи

Печалба преди облагане с данъци

Продажби

Разходи за продажби

Брутна печалба от продажби

Разходи за лихви по дълг

EBITDA

Оперативна печалба

Относно Altimmune Inc

Altimmune, Inc., a clinical stage biopharmaceutical company, focuses on developing treatments for obesity and liver diseases. The company's lead product candidate, pemvidutide, a GLP-1/glucagon dual receptor agonist that is in Phase 2 trial for the treatment of obesity and metabolic dysfunction-associated steatohepatitis. It is also developing HepTcell, an immunotherapeutic product candidate, which is in Phase 2 clinical trial for patients chronically infected with the hepatitis B virus. The company was formerly known as Vaxin Inc. and changed its name to Altimmune, Inc. in September 2015. Altimmune, Inc. was founded in 1997 is headquartered in Gaithersburg, Maryland.